Podcasts about Sequencing

New class every Tuesday. 350+ full classes in the Unlimited Archive at JustGreatYoga.com

In this episode of The Private Equity Podcast, Alex Rawlings is joined for a second time by Brian Gustason, Fractional Operating Partner at BG Operating Advisors.Brian explains why many lower-middle-market businesses struggle to scale after receiving institutional investment and how private equity firms can professionalise their go-to-market strategy.The conversation explores founder dependency, underdeveloped sales and marketing capabilities, and why firms must assess the maturity of the entire revenue engine before attempting to accelerate growth.Brian also outlines the importance of route-to-market analysis, including reach, fit and yield, and explains why growth should be treated as an interconnected system covering marketing, sales and customer success.The episode also examines go-to-market integration within roll-up strategies, the importance of execution fit during due diligence and how operating partners can help portfolio companies sequence growth initiatives more effectively.Key HighlightsWhy founder-led businesses often struggle to scaleThe risks of founder dependency in salesWhat Brian means by “phase zero” capabilitiesWhy firms may need to go backwards before scaling forwardsHow to professionalise a go-to-market strategyThe importance of route-to-market analysisUnderstanding reach, fit and yieldWhy lower-middle-market businesses hit growth ceilingsThe challenges of integrating founder-led businesses in a roll-upWhy go-to-market integration should be pre-wiredThe importance of execution fit during due diligenceWhy growth stalls are not always sales problemsCustomer success versus customer supportHow existing customers can drive expansion revenueSeparating revenue results from the revenue engineHow operating partners can support commercial transformationWhy growth initiatives must be sequenced correctlyTimestamps00:00 – Introduction to Brian Gustason and BG Operating Advisors01:01 – Common growth challenges in the lower-middle market01:31 – Founder dependency and underdeveloped commercial capabilities02:29 – Identifying phase zero go-to-market capabilities03:56 – Defining a professionalised go-to-market strategy04:23 – The role of go-to-market strategy in private equity05:17 – Why route-to-market analysis is often overlooked05:47 – Understanding reach, fit and yield07:14 – Why founder-led businesses often lack scalable processes08:38 – Growth ceilings and limited execution runway10:05 – Go-to-market challenges in roll-up strategies11:34 – Pre-wiring go-to-market integration13:01 – How deal origination affects integration13:58 – Execution fit and time to integration value15:51 – Diagnosing the real causes of stalled growth16:40 – Treating go-to-market as a connected system17:08 – The role of customer success in recurring revenue18:33 – Unlocking growth from existing customers19:53 – Assessing whether the revenue engine can scale20:22 – Separating revenue performance from revenue capability21:20 – Evaluating go-to-market maturity22:42 – Where to play, who to target and how to engage24:10 – How operating partners can support portfolio companies24:37 – The operating partner's role in due diligence25:35 – Identifying businesses that need growth intervention26:31 – Sharing best practices and coaching leadership teams26:59 – Sequencing growth initiatives effectively27:29 – How to connect with Brian Gustason27:57 – Closing remarksRaw Selection partners with Private Equity firms and their portfolio companies to secure exceptional executive talent. We focus on de-risking executive recruitment through meticulous search and selection processes, ensuring top-tier performance and long-term success.

I met Yonatan Sompolinsky in Romania during his summer holiday, so we decided to do a roadtrip interview about covenants, the state of Kaspa development, why intents are more interesting than smart contracts & stag hunts. 00:00:54 – Intro: a road trip with Yonatan Sompolinsky 00:01:50 – Life since S16 E41: Oxford Union & the state of Kaspa 00:02:53 – Kaspa shipped covenants while Bitcoin debates OP_CAT 00:04:24 – Sequencing commitments & based apps explained 00:06:48 – Why OP_CAT alone can't do censorship-resistant based rollups 00:07:21 – BitVM & optimistic vs optimistically verified rollups 00:08:05 – ZK was born for privacy but lives for scaling 00:09:18 – "For the record, I'm very bearish on rollups" 00:12:27 – Ethereum quietly abandons the L2 roadmap 00:13:33 – What ZK is actually for: a thin L1 & separation of layers 00:15:05 – Kaspa follows Bitcoin's UTXO design principles 00:16:04 – Ephemeral logic: generalized atomic swaps 00:17:25 – Camera gymnastics & an Aston Martin 00:19:28 – What covenants won't give you: the DeFi Lego box 00:20:05 – One-time logic vs contract deployment 00:23:18 – The use case question & crypto's crisis of utility 00:26:17 – Bitcoin the turtle & the DAGKnight progress report 00:28:17 – DAGKnight: 49% Byzantine resilience, no latency parameter 00:29:50 – Why 100 BPS on GHOSTDAG would 8x confirmation times 00:30:21 – Sponsors: Cake Wallet, LayerTwo Labs, Braiins, Orange Rock & SideShift 00:34:33 – Zcash made a comeback 00:35:19 – The mental map: where Kaspa is unique 00:38:49 – Real-time decentralization: sampling the honest majority 00:39:47 – Solana & Hyperliquid: fast, but led by one 00:42:46 – Only proof of work bundles proposing & content 00:44:35 – A bear market in usage, not just price 00:45:53 – Old-world use case: bridges & oracles 00:47:22 – Tourism break: Bușteni, mascots & ski resorts 00:49:38 – Hit-and-run agents & the agentic economy 00:51:06 – Having your cake and eating it too 00:54:32 – Vlad on Ecash, miner fees & Satoshi's biggest bet 00:56:37 – Sinaia & the royal train station 00:57:38 – "Bitcoin is dead boring to me at this stage" 00:59:50 – Ironwood, verifiable supply & Tachyon 01:00:39 – Driving like six confirmations 01:01:59 – The tectonic shift nobody noticed: verifying the supply 01:03:43 – The bug & Zcash's unfixable history 01:06:04 – Kaspa's pruning vs historical correctness 01:08:12 – How Zcash's rise paves the way for Kaspa 01:09:17 – The Zooko sleeping-in-the-car story 01:10:32 – "Just launch": Zooko one day before the Sapling bug 01:12:05 – Downplaying the bug & the counterfeit scenario 01:14:34 – Peter Todd's demurrage & the Ironwood migration 01:17:25 – Would any other coin survive this? 01:18:55 – Ethereum's identity crisis 01:21:28 – Back to L1: too little, too late; Solana's cohesion 01:22:46 – Oxford Union & political ambitions 01:24:44 – Hayek: true vs false individualism 01:26:04 – The isolated individual: Lopp, Poelstra & early Bitcoiners 01:32:52 – The enthusiastic individualist 01:34:52 – Coordination markets & Project Stag Hunt 01:35:19 – Prisoner's dilemma vs stag hunt 01:36:24 – Moloch, the demon of defection 01:37:18 – Part 2: stag hunt as the optimistic game 01:42:43 – Intents & NEAR Intents 01:44:03 – Intents vs smart contracts 01:45:21 – Part 3: Rousseau's ape men 01:49:45 – Intendos: "if many sign this, consider mine signed" 01:51:44 – Example: migrating a liquidity pool together 01:53:34 – Pack formation & threshold homomorphic encryption 01:55:42 – Actionable but not committed 01:57:18 – The Netflix example: voice for the scattered majority 02:01:36 – Who are the stags we need to hunt? 02:02:11 – Minarchist, anarchist or libertarian? 02:03:32 – Stag = shared utility; escaping Ethereum's L2 mess 02:06:28 – Composable Intendos 02:07:58 – Exiting network effects 02:09:11 – The Kaspa-Ethereum overlap: GHOST & Casper 02:11:55 – "I don't like DAGs": it's just a data structure 02:12:51 – Why DAGKnight survives a world war 02:15:22 – Michael Sutton & the Argent language 02:16:58 – Bypassing the impossibility theorem 02:18:06 – Ahead of his time or poor communicator? 02:19:31 – BPS vs TPS: the shift already happened 02:21:05 – Falling between the cracks 02:23:17 – The next narrative: coordination markets 02:24:26 – Brașov to Bucharest: documenting the trip 02:25:31 – Roles reversed: Yonatan interviews Vlad 02:27:06 – ACTA protests, internet freedom & political science 02:28:53 – Sztorc's party metaphor 02:29:57 – Zcash at $30 & the Coldcard hack 02:31:40 – What Kaspa actually needs: wallets, not exchanges 02:33:56 – Broadening cypherpunk: from protective to positive 02:37:16 – What have we really accomplished? 02:39:33 – Arriving at the Palace of Parliament 02:43:57 – The secret handshake & farewell

In this week's episode Brian and Jeff discuss why Social Security timing is really a tax sequencing decision and the Ripple Effect - how one tax decision can raise your Medicare premiums. 

Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics: Introduction (0:00) Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22) Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24) Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31) Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01) Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24) CME information and select publications

Welcome back to the Jack Westin MCAT Podcast with Mike and Molly! Last episode we covered DNA and RNA structure. Now we put that knowledge to work and answer the question that follows naturally: how do scientists actually study DNA, and how does the MCAT test those techniques?This is the DNA techniques episode, and it connects back to nearly everything you have already learned including amino acids, protein structure, hemoglobin, gel electrophoresis, blotting and central dogma.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HMB865. CME/EBAH/NCPD/CPE/AAPA credit will be available until July 24, 2027.Mapping the Pathways to Long-Term Treatment Benefit in Chronic Lymphocytic Leukemia (CLL): Strategies for Aligning Patient Priorities With Evidence for Initiating & Sequencing Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HMB865. CME/EBAH/NCPD/CPE/AAPA credit will be available until July 24, 2027.Mapping the Pathways to Long-Term Treatment Benefit in Chronic Lymphocytic Leukemia (CLL): Strategies for Aligning Patient Priorities With Evidence for Initiating & Sequencing Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HMB865. CME/EBAH/NCPD/CPE/AAPA credit will be available until July 24, 2027.Mapping the Pathways to Long-Term Treatment Benefit in Chronic Lymphocytic Leukemia (CLL): Strategies for Aligning Patient Priorities With Evidence for Initiating & Sequencing Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HMB865. CME/EBAH/NCPD/CPE/AAPA credit will be available until July 24, 2027.Mapping the Pathways to Long-Term Treatment Benefit in Chronic Lymphocytic Leukemia (CLL): Strategies for Aligning Patient Priorities With Evidence for Initiating & Sequencing Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

In today's episode, we spoke with Marlana M. Orloff, MD. Dr Orloff is the Alexander & Johnston Family Endowed Clinical Director in Uveal Melanoma, and associate professor at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. In our exclusive interview, Dr Orloff discussed the distinct biology of uveal melanoma and why it has historically resisted systemic treatment. Unlike cutaneous melanoma, which carries a high tumor mutational burden and responds robustly to immune checkpoint inhibitors, uveal melanoma sits at the opposite end of the spectrum with low mutational burden, a predominantly liver-metastatic pattern, and an immune-tolerant microenvironment that renders traditional immunotherapy largely ineffective.She provided context on the treatment landscape for patients with HLA-A*02:01–negative metastatic uveal melanoma prior to the phase 2/3 OptimUM-02 trial (NCT05987332), noting that this population had limited options: liver-directed therapies such as percutaneous hepatic perfusion, off-label immune checkpoint inhibitor combinations, or clinical trial enrollment.Dr Orloff then walked through the design and efficacy findings of the trial, which evaluated the combination of darovasertib, an oral PKC inhibitor, plus crizotinib (Xalkori), a MET inhibitor, vs investigator's choice in treatment-naive, HLA-A*02:01–negative patients. The combination demonstrated a median progression-free survival of 6.9 months vs 3.1 months with investigator's choice, with an objective response rate of 37.1% compared with under 5.8% in the control arm. She highlighted the clinical significance of the complete responses observed while noting that overall survival data from the phase 3 portion of the trial remain pending.The discussion also addressed the growing complexity of treatment sequencing as more options emerge, including tebentafusp-tebn (Kimmtrak) for HLA-A*02:01–positive patients, liver-directed and combination approaches, and the investigational TCR-engineered T-cell therapy anzutresgene autoleucel targeting PRAME. Dr Orloff emphasized that in the absence of head-to-head comparisons, sequencing decisions will increasingly be shaped by patient logistics, toxicity profiles, and access to specialized treatment centers.

Chris Ballew is BACK for his fifth Power Chord Hour appearance to talk about his 11th solo album Newborn Human, the making of the Presidents 1996 sophomore album II, if it's harder to open or close and album and lots more CHRIS BALLEW https://chrisballew.org https://chrisballew.bandcamp.com https://www.instagram.com/chrisballew https://www.instagram.com/pusaband PCH Instagram - www.instagram.com/powerchordhour Facebook - www.facebook.com/powerchordhour Youtube - www.youtube.com/channel/UC6jTfzjB3-mzmWM-51c8Lgg powerchordhour@gmail.com Donate to help show costs - https://www.paypal.com/paypalme/pchanthony https://cash.app/$anthmerch Check out the Power Chord Hour radio show every Friday night at 8 pm est/Tuesday at Midnight est on 107.9 WRFA in Jamestown, NY. Stream the station online at wrfalp.com/streaming/ or listen on the WRFA app/Apple CarPlay/Android Auto

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUQ865. CME/MOC/EBAH/NCPD/CPE/AAPA credit will be available until July 9, 2026.Rethinking the CLL Treatment Sequence: Guidance on Selecting and Sequencing Modern Treatment for Sustained Efficacy Across Lines of Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUQ865. CME/MOC/EBAH/NCPD/CPE/AAPA credit will be available until July 9, 2026.Rethinking the CLL Treatment Sequence: Guidance on Selecting and Sequencing Modern Treatment for Sustained Efficacy Across Lines of Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUQ865. CME/MOC/EBAH/NCPD/CPE/AAPA credit will be available until July 9, 2026.Rethinking the CLL Treatment Sequence: Guidance on Selecting and Sequencing Modern Treatment for Sustained Efficacy Across Lines of Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUQ865. CME/MOC/EBAH/NCPD/CPE/AAPA credit will be available until July 9, 2026.Rethinking the CLL Treatment Sequence: Guidance on Selecting and Sequencing Modern Treatment for Sustained Efficacy Across Lines of Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

In today's episode, we spoke with Neil D. Gross, MD, FACS. Dr Gross is the medical director of Perioperative Surgical Services, section chief of Oropharynx Cancer, Surgery, and professor of head and neck surgery at The University of Texas MD Anderson Cancer Center in Houston. In our exclusive interview, Dr Gross discussed the key biological and clinical distinctions between cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC), noting that although BCC is more indolent and less responsive to systemic therapies, including immunotherapy, CSCC carries a meaningful risk of nodal and distant metastases and has demonstrated robust responses to anti–PD-1 therapy, with approximately half of patients achieving a significant response.He emphasized the importance of early multidisciplinary evaluation, with resectability serving as a critical first branch point in treatment planning. For patients with unresectable or metastatic CSCC, anti–PD-1 therapy is now the established standard of care. For borderline resectable patients, such as those at risk for significant functional loss from surgery, upfront systemic therapy offers the potential to preserve function and achieve cure. For resectable, high-risk patients, Gross highlighted the role of adjuvant cemiplimab-rwlc (Libtayo) following surgery and radiation, based on data from the phase 3 C-POST trial (NCT03969004).The discussion also addressed toxicity considerations in elderly and immunocompromised patients, populations Gross described as particularly high risk and underserved. He noted that although anti–PD-1 therapies are generally well tolerated, serious toxicities remain possible, underscoring the importance of careful patient monitoring in both adjuvant and investigational neoadjuvant settings.Finally, Gross highlighted the actively accruing phase 3 NRG-HN014 trial (NCT06568172), a National Cancer Institute–sponsored cooperative group study open across the United States, Canada, and Australia, which is evaluating a neoadjuvant approach vs upfront surgery in patients with advanced resectable CSCC. He also noted that more mature data from C-POST, as well as long-term phase 2 neoadjuvant findings, are anticipated later this year. [CS1]https://faculty.mdanderson.org/profiles/neil_gross.html

Please visit answersincme.com/TNM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Richard Kim, MD. In this activity, an expert in oncology discusses when and how to sequence later-line and chemotherapy-free therapies in metastatic colorectal cancer (mCRC). Upon completion of this activity, participants should be better able to: Evaluate factors influencing a treatment switch from cytotoxic agents for patients with stable metastatic colorectal cancer (mCRC); Formulate practical approaches for transitioning from chemotherapy to tyrosine kinase inhibitor (TKI) treatment in later-line settings for patients with mCRC; and Describe strategies to prolong chemotherapy-free disease control with TKIs.

Please visit answersincme.com/TNM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Richard Kim, MD. In this activity, an expert in oncology discusses when and how to sequence later-line and chemotherapy-free therapies in metastatic colorectal cancer (mCRC). Upon completion of this activity, participants should be better able to: Evaluate factors influencing a treatment switch from cytotoxic agents for patients with stable metastatic colorectal cancer (mCRC); Formulate practical approaches for transitioning from chemotherapy to tyrosine kinase inhibitor (TKI) treatment in later-line settings for patients with mCRC; and Describe strategies to prolong chemotherapy-free disease control with TKIs.

Dr. Pedro Barata and Dr. Giuseppe Curigliano discuss the rapid paradigm shift of antibody-drug conjugates into frontline advanced and curative-intent perioperative settings and the clinical challenges of optimal sequencing, target selection, and cross-resistance. LINK TO FULL TRANSCRIPT

In this episode, Dr. Marc Pietropaoli discusses his transition from traditional orthopedics to regenerative medicine, emphasizing the importance of repairing rather than replacing damaged joints. He shares insights on the components and sequencing of regenerative treatments, the role of genetic testing in nutrition, and his mission to eliminate the need for knee replacements by 2043. The conversation highlights the significance of prevention and proactive care in joint health. In this conversation, Dr. Marc Pietropaoli discusses various aspects of injury prevention, particularly focusing on ACL injuries and innovative surgical techniques. He emphasizes the importance of proper landing techniques, dynamic warm-ups, and the role of proprioception in preventing injuries. The discussion also covers the advancements in ACL repair, including the bear procedure, which utilizes a collagen implant to enhance healing and reduce the risk of arthritis. The conversation concludes with resources for further learning and insights into the future of sports medicine.   For Audience Join the other 20,000+ high-performers getting weekly insights on biological reversal, exponential strategies, and Life Energy optimization→ https://start.gladdenlongevity.com/subscribe If you're ready to measure your 60+ biological ages and build a personalized reversal plan, apply for a discovery call here → https://start.gladdenlongevity.com/apply-now   Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/!      Takeaways        Dr. Pietropaoli transitioned from traditional orthopedics to regenerative medicine.        He emphasizes the body's ability to heal itself through regenerative techniques.        The importance of asking questions in medical training is highlighted.        Dr. Pietropaoli's personal experiences influenced his career path.        He advocates for a team approach in patient care, involving various specialists.        Inflammation is a key factor in joint health and must be addressed.        Genetic testing can guide nutritional choices for better health outcomes.        Preventive measures can significantly reduce the risk of joint injuries.        Dr. Pietropaoli aims to end the need for knee replacements by 2043.       The conversation underscores the importance of patient education in exploring treatment options. Bending knees during landing reduces injury risk.        Proper proprioception is crucial for athletes.        Dynamic warm-ups are more effective than static stretching.        Mastering two-legged exercises is essential before progressing to one-legged ones.        Plyometrics enhance fast twitch muscle fiber development.        Agility is linked to balance and quickness.        Bear surgery offers a promising alternative to traditional ACL repair.        Collagen implants can significantly aid in ACL healing.        Using blood flow restriction can enhance recovery post-surgery.        Education and awareness are key in sports injury prevention.     Chapters 00:00 Introduction to Regenerative Orthopedics 04:08 The Journey from Traditional to Regenerative Medicine 13:46 Components and Sequencing in Regenerative Treatments 20:04 Genetic Testing and Nutrition for Optimal Health 22:52 Future Aspirations in Joint Health and Prevention 27:09 Injury Prevention Techniques 34:06 Understanding ACL Injuries and Repair 42:35 Innovations in ACL Surgery 45:34 Resources and Final Thoughts   To learn more about Dr. Marc: Website: www.victoryinmotion.com TikTok: https://www.tiktok.com/@drmarcpietropaoli Instagram: https://www.instagram.com/drmarcpietropaoli LinkedIn: https://www.linkedin.com/in/drmarcpietropaoli YouTube: https://www.youtube.com/@victoryinmotion1   Reach out to us at:    Website: https://gladdenlongevity.com/     Facebook: https://www.facebook.com/Gladdenlongevity/    Instagram: https://www.instagram.com/gladdenlongevity/?hl=en     LinkedIn: https://www.linkedin.com/company/gladdenlongevity    YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw     Gladden Longevity Podcast Disclosures Production & Independence The Gladden Longevity Podcast and Age Hackers are produced by Gladden Longevity Podcast, which operates independently from Dr. Jeffrey Gladden's clinical practice and research at Gladden Longevity in Irving, Texas. Dr. Gladden may serve as a founder, advisor, or investor in select health, wellness, or longevity-related ventures. These may occasionally be referenced in podcast discussions when relevant to educational topics. Any such mentions are for informational purposes only and do not constitute endorsements. Medical Disclaimer The Gladden Longevity Podcast is intended for educational and informational purposes only. It does not constitute the practice of medicine, nursing, or other professional healthcare services — including the giving of medical advice — and no doctor–patient relationship is formed through this podcast or its associated content. The information shared on this podcast, including opinions, research discussions, and referenced materials, is not intended to replace or serve as a substitute for professional medical advice, diagnosis, or treatment. Listeners should not disregard or delay seeking medical advice for any condition they may have. Always seek the guidance of a qualified healthcare professional regarding any questions or concerns about your health, medical conditions, or treatment options. Use of information from this podcast and any linked materials is at the listener's own risk. Podcast Guest Disclosures Guests on the Gladden Longevity Podcast may hold financial interests, advisory roles, or ownership stakes in companies, products, or services discussed during their appearance. The views expressed by guests are their own and do not necessarily reflect the opinions or positions of Gladden Longevity, Dr. Jeffrey Gladden, or the production team. Sponsorships & Affiliate Disclosures To support the creation of high-quality educational content, the Gladden Longevity Podcast may include paid sponsorships or affiliate partnerships. Any such partnerships will be clearly identified during episodes or noted in the accompanying show notes. We may receive compensation through affiliate links or sponsorship agreements when products or services are mentioned on the show. However, these partnerships do not influence the opinions, recommendations, or clinical integrity of the information presented. Additional Note on Content Integrity All content is carefully curated to align with our mission of promoting science-based, ethical, and responsible approaches to health, wellness, and longevity. We strive to maintain the highest standards of transparency and educational value in all our communications.  

Molecular biology is more than a set of techniques. It is a toolkit for asking better questions. In this special crossover episode of Speaking of Mol Bio, Steve Lewis welcomes Jordan Ruggieri, Senior Marketing Manager at Thermo Fisher Scientific and co-host of the Absolute Gene-ius podcast. Jordan shares how Absolute Gene-ius began with a focus on digital PCR and evolved into a broader celebration of molecular genetics, genomics, and the scientists using diverse tools across multiple research areas. From endpoint PCR and qPCR to digital PCR, sequencing, sample prep, and downstream analysis, the conversation highlights how different technologies work together to help researchers move from sample to answer. Jordan also reflects on memorable podcast stories, including Antarctic microbial research, transplant science, lab mishaps, and the ways PCR-enabled discoveries can have real-world human impact. The episode also explores themes that run through many scientific careers: curiosity, grit, mentorship, failure, and openness to unexpected opportunities. Jordan shares his own path from aspiring dentist to R&D scientist, marketer, and podcast host, while offering early-career scientists practical advice: stay open, keep learning, and make time for hobbies and life outside the lab. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

In this special episode, we revisit a fireside conversation between Vitalik Buterin and Friederike Ernst at DappCon 2026 in Berlin. They explore the Ethereum Economic Zone (EEZ), a new vision for Ethereum built around synchronous composability, app chains, and real-time proving.Following the fireside, Sebastien and Friederike break down the ideas behind the EEZ and discuss what this new paradigm could mean for Ethereum's future.Topics covered include:• The Ethereum Economic Zone and synchronous composability• App chains, privacy networks, and prediction markets• Ethereum as an economic operating system for the internet• Sequencing, MEV, and shared liquidity across chains• Enterprise, government, and institutional use cases• Why this approach differs from Cosmos, Polkadot, and other ecosystem visions• The future of Ethereum beyond rollup fragmentationLinks:Lido: https://lido.fi/stvaults?mtm_campaign=epicenterSponsors: Lido V3 introduces stVaults: a modular staking infrastructure that lets builders and institutions deploy custom staking vaults, while staying anchored to stETH as a shared liquidity layer.Get started building with Lido V3 today: https://lido.fi/stvaults?mtm_campaign=epicenterBlock Space Forum: https://blockspace.forum/NEAR AI Cloud now lets developers deploy OpenClaw—the rapidly growing open-source AI agent platform—inside Trusted Execution Environments, providing hardware-level encryption with cryptographic attestations. With OpenClaw on NEAR AI Cloud, you can run agents with cloud convenience, but without traditional cloud data exposure. No hardware to manage. No trust assumptions required. Learn more at near.ai.

Sequencing departures like a moving puzzle, scrambling when a jet takes off without clearance, and catching what radar misses with a glance out the window with Michael Rejent, an air traffic controller. What does "tally ho" mean to a pilot? What phrase makes every controller in the cab look up?WANT MORE EPISODE SUGGESTIONS? Grab our What It's Like To Be... "starter pack". It's a curated Spotify playlist with some essential episodes from our back catalogue.GOT A COMMENT OR SUGGESTION? Email us at jobs@whatitslike.comFOR SPONSORSHIP OPPORTUNITIES: Email us at partnerships@whatitslike.comWANT TO BE ON THE SHOW? Leave us a voicemail at (919) 213-0456. We'll ask you to answer two questions:1. What's a word or phrase that only someone from your profession would be likely to know and what does it mean?2. What's a specific story you tell your friends that happened on the job? It could be funny, sad, anxiety-making, pride-inducing or otherwise.We can't respond to every message, but we do listen to all of them! We'll follow up if it's a good fit.

In today's episode, we spoke with David O'Malley, MD. Dr O'Malley is a professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–James in Columbus, Ohio. In our exclusive interview, Dr O'Malley discussed his approach to treatment selection and sequencing in platinum-resistant ovarian cancer, a disease setting he described as representing the highest unmet need in the field. He emphasized the central role of clinical trial enrollment and biomarker-driven decision-making, alongside practical patient-centered considerations, such as infusion schedule and quality of life.He highlighted the growing importance of antibody-drug conjugates (ADCs) in this setting, noting that folate receptor alpha and HER2 are the two biomarkers most relevant to current practice. Dr O'Malley outlined how National Comprehensive Cancer Network guidelines support treatment across a broader range of expression levels than initial approvals reflected, citing emerging data suggesting activity even at lower expression thresholds. He also addressed payload sequencing, explaining that outside of a clinical trial, he currently uses topoisomerase I–based ADCs and antimicrotubule-based ADCs each one time only, and remains open to targeting the same antigen again if the payload differs.The discussion also touched on combination strategies, resistance biology, and the evolving role of immunotherapy following the survival benefit observed with pembrolizumab (Keytruda) in the phase 3 KEYNOTE-B96 trial (NCT05116189). Dr O'Malley expressed enthusiasm for next-generation payloads, dual-target approaches, and the potential for bispecific antibodies and novel DNA damage response–targeting agents to define the post-ADC treatment landscape.Finally, Dr O'Malley underscored the need for more tumor biopsies to better characterize resistance mechanisms and called for expanded pharmaceutical investment in retreatment and cross-resistance studies to guide future sequencing decisions.

The follow-up mistake that costs sales (and kills communication) is a lack of sequencing. If I’ve got a sequence in place that says, all right, when I get a lead from a networking function, I’m going to initially, either same day or next morning, send out this email message, which essentially says, “it was great meeting you at the networking function. Nice having a chance to talk.” Then, you include something in that email to elicit a response. Some will initiate a dialogue, some of them won’t. So from that point, if you don’t hear back, you could have another one that goes out a couple of days later saying, “Hey, never heard back you on this, but something else occurred to me that I didn’t mention…” and then you add something else to the conversation that could potentially be of interest to them. So you’re not just hitting them with “call me, call me, call me, call me.” You’re actually creating value in the communication, which is particularly key when you’re doing sequencing like that. David: Hi, and welcome to the podcast. In today’s episode, co-host Jay McFarland and I will be discussing the topic of sequencing your communication. Welcome back, Jay. Jay: Hey, David. Great to be with you again. I really love that we dive into these things that can have such an impact on your daily business. Oftentimes people will focus on the large things, not understanding that sometimes the smallest tweaks can make all the difference. David: Yeah, and things like this really are kind of diving deep. And many times I know other people in podcasts or in stuff that’s actually going out to the public, they’ll just keep it all high level and not really get into too much. I think we’ve done a reasonably good job over the years of diving a little deeper and getting into things in a little bit more detail. Because it’s important for people who watch this or listen to this to recognize that there are a lot of aspects to all of this. And we touched on this in the previous episode. We were talking about sort of the high level goals, we were talking about the high level concepts versus the nitty gritty of what do I have to do on a day-to-day basis. And this really gets more into the idea of the nitty gritty. But sequencing is something that I don’t hear many people talk about in business. And I think it’s a real game changer for people in the sense that when you get this and you start implementing it, it changes the way that you interact with your prospects and clients to make what you are doing better and more appealing than what your competition is probably doing. Jay: Yeah, such a great point. And back to the idea of focusing on the smaller stuff. I’m weird. I call myself lazy because I want to avoid steps and reduce steps, but in the name of that laziness, I will spend weeks trying to create a system, whether it’s a software system or a planning system or something, just knowing that over the long run, it’s going to have such a dramatic impact. And I can be lazy about that thing after that. And I focus. I mean, if I can reduce one little step, I’ll spend weeks trying to figure out how to do that. David: Yeah. But that’s smart. I don’t think that’s lazy. I think it’s far lazier to just go into each situation, not knowing what’s going to happen, not knowing how to respond to the common objections you get, not knowing how to create a system that will allow you to bring clients through the door like clockwork. And when you do that, you’re basically going into work every day with no idea of what’s going to happen. So I think that’s really lazy and really sloppy and I don’t think what you described is lazy at all. Jay: Well, I don’t, you know, I think you’re probably right, but it is something that drives my wife crazy and it’s really bad. Like when we go grocery shopping, I have a route, and that route has a very specific design. It’s based upon how the groceries are going to end up on the conveyor belt. And that’s important because that determines on how they will go into the bags, because I want the bread on top and all of those things on top. So I have this all planned and thought out from years of experience. It brings me joy, David, it’s, it’s a little, probably obsessive compulsive, but that’s the way I am. David: That’s funny and she still lets you come along. That’s amazing. But it’s a great example though, because when you think about that, and there are two schools of thought when it comes to outcomes, right? You described a more outcome driven approach. And it reminds me of the expression, the road is better than the inn, if you’ve heard that one. Jay: Mm-hmm. David: And I remember hearing that years ago and thinking, no, I kind of like the inn, right? I like, where are we going? Let’s get there. Mission accomplished. Onto the next thing. But there are people who just enjoy the experience. Shopping is a great example of that. I have never been a good shopper. Jay: Mm-hmm. At least before online shopping. I was a terrible shopper. As a kid. My mom would drag me around to different stores and she could just look at stuff for hours. I got bored three minutes in. As a kid, I could go to the toy section and I could look around for a few minutes, maybe see something I liked or whatever. Then I’m done. Right? And people are just wired differently in that regard. But I think if we really get down to the core of it, and we start thinking in terms of creating the systems and processes that will allow you to get results in your business, and tying it again back to our main topic, sequencing your communication, what this will allow you to do is to leapfrog your competition. Because you won’t have to think about each step of it. And it really ties to what you were saying about, you know your process in a store. Well, imagine that in business. Imagine a situation where you create a sequence of communications to send out to the prospects that you want to convert, in a specific order, in a specific sequence, at a specific timeframe. You can automate that as well. And design it to accomplish a result Too often in business because we’re sort of focused all over the place, we’re here, we’re there, we’re everywhere. We think in terms of sending a message out to a prospect and waiting for them to reply. And when they don’t reply. We become confused and annoyed. It’s like, why didn’t they reply? I sent you an email. Why didn’t you reply? And it’s cause that’s not the way the world works anymore. Right? I sent you an email. Yeah, it’d be nice if it were like tennis, where you bat it across the other person bats it across, and you bat it across and you have a nice volley going. That happens sometimes, but more often than not, it’s not happening. And if you’re depending on getting that volley hit back to you right away, you’re setting yourself up for failure. Where instead, if you recognize, you may have to send it across the net 3, 4, 5, 7, 10 times before it gets lobbed back, you’ll be prepared. And if you prep that in advance, you are so far ahead of what your competition is doing. It’s just not even funny. Jay: Yeah, I, have this situation going on right now where somebody has sent me an email inviting me to do something. I don’t know who this person is. I’ve never heard from them, and then I don’t respond. And then like four days later, I get an email that says, Hey, you didn’t respond. And I’m like, Well, that should tell you all you need to know. And then I got another one. I’ve sent you two emails and you haven’t responded. This person is sequencing, but they’re doing it in a horrific way. I mean, by the third email, I’m like, who do you think you are? That you can sit here and demand a response from me? And I don’t even know who you are. The whole thing has soured me. I am never going to call them back based upon that type of sequencing. David: Right. And if that’s the type of sequencing we’re talking about, then yeah, don’t do that. That is not what I’m talking about. It’s interesting you should mention that because over the past several months I have received so many messages from people, pitching guests for this very podcast where they’re saying, Hey, I think you should interview this person who’s talking about this thing, and let me know if that’s of interest to you. You know, I’ve listened to your podcast. I think he’d be a great fit. And most of the time I get, you know, pretty much the same pitch for different speakers. So I’m on some kind of list and I normally ignore them. But they’ve got sequences set up where it’s the second one. Hey, just bumping this up to the top of your inbox again, you know, do you want to consider so-and-so for the podcast? And so finally, I just put together the response that I’m sending to people, which is to say, if you listen to this podcast, you would recognize that we are not an “interview of the week kind of thing.” You know, there are two of us who do this. Jay: Yeah. David: If we were a podcast that had a lot of people on and we were interviewing what you said would make sense, and I don’t get into all that much detail. But they’re basically not pitching the right thing to the right person. And so in those situations, yeah, sequencing is not a great idea. But when you’ve got somebody who is engaged or would like to be engaged and you want to find out whether or not they’re on board with you, when it’s done right… And that ties into the MVPs, the messaging, you know, is the messaging going to be good? Which combination of marketing vehicles you’re using to reach them, and who are the people you’re reaching? If you’ve got those three things in sync, then sequencing is going to work extremely well for you. Jay: So let’s talk a little bit more about. Sequencing. I can guess at a, couple of these things. I’m guessing like so many of the things we’re talking about, you want to start with pen and paper and maybe start identifying who your potential customers are. What are potential, the stages that they might be in, and then start focusing on the messaging for each of those stages. David: Yes. And when we think in terms of the overall stages, or the initial stages, where is this person in the journey? If this is somebody that I just met, let’s say I meet somebody at a networking function. We exchange business cards or whatever, I go back to my office, this person goes back to their office and nothing happens until one of us moves, right? So, If I’ve got a sequence in place that says, all right, when I get a lead from a networking function, what I’m going to do is I’m going to initially, either same day or next morning, send out this email message, which essentially says, it was great meeting you at the networking function. Nice having a chance to talk. And then. you have something that you say and obviously it’s going to be different for each person who’s doing that, but you’ve got something that is said in that email that is designed to elicit a response. So you might want to end that email with a question so that they’re likely to initiate a dialogue. Some will initiate a dialogue, some of them won’t. So from that point, if you don’t hear back, you could have another one that goes out a couple of days later like, with a reply to your own message saying, Hey never heard back you on this, but something else occurred to me that I didn’t mention… and then you add something else to the conversation that could potentially be of interest to them. So you’re not just hitting them with call me, call me, call me, call me. You’re actually creating value in the communication, which is also key to good marketing, but it’s also particularly key when you’re doing sequencing like that. And then the third step in your sequence could be calling to follow up. If they gave you a business card, it could be a phone call that comes whatever, a week later or a certain period of time later, and you decide what that is. In our Total Market Domination course, I mean, we walk through all of this so people can decide, can determine for themselves what is a good timeframe to do this in. Because a lot of times if you get a business card from somebody at a networking function and you forget about it? Or you go to a trade show, that’s the worst! You’re paying to have all these people go out to the trade show. You’re paying to put ’em up, you’re paying to feed them. They bring cards back and they stay in the bottom of their briefcase or their suitcase. And those people never get phone calls. It’s just such an incredible waste. But if you’ve got these processes in place to be able to sequence your communication, to be able to get those people back into the zone that they were in, that first initiated the conversation, then they will be far more likely to respond to you and reply to the conversation and keep it going. Jay: Yeah, it’s interesting. I’m in the heat of this process right now, because as you know, I’m setting up a new business. David: Mm-hmm. Jay: building the CRM behind the scenes and I have to ask myself, what are each of the stages and what do I want to happen? What type of communication? And one of the other parts about that, that is so important is, oftentimes, I know when I’ve been put in somebody’s CRM drip system. Because the messages stop being personal and I’m like, you’re sending this out to everybody. So there’s a fine line between having a sequence and making people feel like, oh, they’ve just been put in the hopper. I think we have a high awareness. And so I think that your sequences need to be a combination of personal contact. And these systems that will save you a lot of time and effort. David: Yes, I agree completely. I also think that the way that those sequences are written is going to determine a lot of that as well. Jay: Yes! David: There are people in business, many of us in business have initially been trained on “corporate speak.” And we write in brochure language, instead of in human language. Jay: Yes. David: A lot of what you just described can be overcome simply by engaging in conversational English, even in the messages that are going out automatically. Even in the automated messages where much of the content will be the same. But the way that you’re conveying it still seems more personal and still feels like it’s coming from another human being as opposed to an auto-generated sequence. Jay: Yeah. David, I love this point. And you know, I’ve discovered a way for me to do this. And that is I’ve started using dictation on the computer a lot. Because I don’t know if people notice if they’re watching the video. I have something called Essential Tremors, which causes me to shake. And it’s getting harder and harder for me to type. So I’ve gone to dictation, but I found if I close my eyes and I act like I’m on the phone with the person when I’m doing the dictation, that brochure speak goes away. And so it’s something I don’t have to give a lot of thought to. It’s just a change in how I’m recording that information. David: Yeah, I do a very similar thing on the treadmill in the morning. I’ve got a, a little digital recorder and I’m on the treadmill and I’m moving and I’m recording. It could be a letter, it could be notes for some sort of presentation I’m going to do. But I will record that and I’ll just stop it every few seconds. If you heard those recordings, it’s a lot of heavy breathing and little bits and pieces. And I’ll say three words and I’ll stop and I’ll try to figure out what the rest of the sentence is, and I’ll say that, and then I’ll just take that whole thing and I’ll get it transcribed. And then at that point I can clean up the words and it’s a hundred times easier than trying to sit down in front of a blinking cursor and figure out what I’m going to say next. Jay: Yeah. And that blinking cursor, it does something to us. It changes how, how we record that information. So I love that piece of feedback when it comes to sequencing. Cool. How do people find out more, David? David: You can go to top secrets.com/call, schedule a call with myself or my team if you are interested in getting better response from people by thinking things out in advance and sequencing your communication so that people are actually looking forward to hearing what you have to say next instead of dreading it, schedule a call. Jay: Yeah, absolutely. David, once again, it’s a pleasure talking to you. David: Thank you so much, Jay. Are You Ready to Start Getting Better Results by Sequencing Your Communication? If so, check out the five primary ways we help promotional product distributors grow: Just Getting Started? If you (or someone on your team) is just getting started in promotional products sales, learn how we can help. Need Clients Now? If you're already grounded in the essentials of promotional product sales and just need to get clients now, click here. Want EQP/Preferential Pricing? Are you an established industry veteran doing a significant volume of sales? If so, click here to get End Quantity Pricing from many of the top supplier lines in the promo industry. Time to Hire Salespeople? If you want to hire others to grow your promo sales, click here. Ready to Dominate Your Market? If you're serious about creating top-of-mind-awareness with the very best prospects in your market, schedule a one-on-one Strategy Session here.

Ann M Moyer, Emma Lundquist, Emily K Thoreson, Michelle L Kluge, Katrina E Kotzer, Elyse M Love, Heather L Glessner, Sarah K Arneson, Loralie J Langman, Linnea M Baudhuin, John Logan Black. DPYD Sequencing Identifies More Clinically Relevant Variants as Compared to Targeted Genotyping. Clinical Chemistry, Volume 72, Issue 6, June 2026, Pages 662–669. https://doi.org/10.1093/clinchem/hvag007.

What does it take to go from working at the bench to becoming a future clinical microbiology laboratory director? In this episode, Luis is joined by Dr. Mackenzie Collins, a CPEP fellow at UCLA, to discuss her journey from Medical Laboratory Scientist (MLS) to PhD scientist and CPEP fellow. Mackenzie shares how she discovered laboratory medicine, her experience working as an MLS in molecular microbiology, and the mentors and opportunities that helped shape her career path. The conversation explores the CPEP fellowship, the role of laboratory directors, and how MLS professionals can strengthen their applications through projects, research, presentations, and professional involvement. Mackenzie also discusses her PhD work involving HIV reservoirs and long-read sequencing, and why genomics and molecular diagnostics will continue to play an increasingly important role in clinical microbiology. Whether you're considering graduate school, interested in the CPEP fellowship, or exploring career paths in laboratory medicine, this episode offers a firsthand look at one MLS's journey from the bench to clinical microbiology leadership. Topics discussed: The MLS-to-CPEP pathway and transitioning from the bench to graduate school Mentorship, professional development, and building a competitive application The role of clinical microbiology laboratory directors and career opportunities beyond the bench Sequencing, genomics, and the future of clinical microbiology Additional Resources CPEP Fellowship Overview with Dr. Sam Goodfellow Interested in learning more about the CPEP Fellowship? In this episode, Dr. Sam Goodfellow discusses the structure of the program, the application process, and what to expect from CPEP training. https://directory.libsyn.com/episode/index/id/36395120 Understanding the ABMM Certification Examination Learn more about the American Board of Medical Microbiology (ABMM) certification, its importance for future laboratory directors, and what candidates can expect from the examination process. https://directory.libsyn.com/episode/index/id/35868345 Stay connected with Let's Talk Micro: Website: letstalkmicro.com Questions or feedback? Email me at letstalkmicro@outlook.com Interested in being a guest on Let's Talk Micro? Fill out the form here: https://forms.gle/V2fT3asjfyusmqyi8 Support the podcast: Venmo Buy me a Ko-fi  

What if one proven methodology could turn B2B market share from stagnant to soaring, with a track record of guaranteed growth, yet almost no U.S. company has heard of it? In this episode of Predictable B2B Success, we speak with Hugo Van Den Biggelaar, a former Nike brand strategist turned evangelist for Bitsing, a 33-year-old European methodology that has fueled BMW, Shell, HP Enterprise, and thousands of organizations, with no failures on record. Hugo, now based in Brooklyn, New York, challenges core assumptions about B2B growth. He says most companies aren't failing because they do the wrong things, but because they do the right things in the wrong order and at the wrong time. What is the hidden sequence behind sustained revenue, and why is “brand awareness” sometimes a death trap? Hugo reveals why even the most successful B2B teams often aim at the wrong goals, how to build a “golden egg” competitors can't copy, and why emotional preference, not rational decision-making, drives billion-dollar deals. Why your growth efforts stall or how sales, marketing, and product can actually align, this conversation will leave you rethinking everything you know about predictable B2B success. Some topics we explore in this episode include: The Bitsing Methodology: Origins, proven track record, and impact on companies worldwideRight Actions, Wrong Sequence: How companies undermine growth by doing the right things in the wrong orderFinancial Goal Setting: The necessity of clear financial (not just KPI) goals: continuity, ambition, and dreamOrganizational Alignment: The need for unified goals and eliminating departmental silosThe Seven Principles/Steps: The stepwise framework that drives predictable growthData-Driven Focus: The Pencil Method: Using facts (not gut) to determine where revenue actually comes fromThe Golden Egg: Emotional Differentiation: Creating an emotional, uncopyable reason for customers to choose your brandStrategies vs. Goals: The common mistake of confusing means with ends 17:12.Driving Preference and Loyalty: Preference as the key to growth and how to create genuine, unconditional loyaltyPlan Execution & Guaranteed Results: The phases of implementation and what “guaranteed growth” means with Bitsing

What matters most to patients with non-muscle invasive bladder cancer (NMIBC)? In this episode of BackTable Urology, Dr. Kelly Bree, Dr. Saum Ghodoussipour, and Meredith Donahue, N.P., join host Dr. Vignesh Packiam to discuss the power of shared decision-making across the NMIBC spectrum. They explore risk-adapted treatment selection, when to escalate or de-escalate therapy, and how to navigate conversations about recurrence risk, treatment burden, quality of life, and the possibility of cystectomy. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Johnson & Johnson. --- Timestamps 00:00 - Introduction01:55 - Second Opinions and Patient Counseling06:08 - Intermediate Risk Stratification12:13 - Treatment Options for Intermediate Risk NMIBC16:20 - BCG and Alternative Treatments for High Risk NMIBC26:49 - Options for BCG-Unresponsive NMIBC31:42 - Sequencing and Cystectomy37:03 - Financial and Time Toxicity41:08 - Biomarkers and ctDNA44:04 - Future Trials and NMIBC Innovations --- More about this episode They also review emerging therapies such as ZUSDURI, the evolving role of intravesical treatments, and the promise of biomarkers and ctDNA for personalized care. The discussion covers practical strategies for patient counseling, key updates to clinical guidelines, and a preview of innovations shaping the future of NMIBC management. --- Resources Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial:https://pubmed.ncbi.nlm.nih.gov/41571573/ Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancerhttps://ascopubs.org/doi/10.1200/JCO-25-01324 CIRCULATING TUMOR DNA AS A BIOMARKER FOR UPSTAGING AND ADVERSE PATHOLOGY IN HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER:https://www.auajournals.org/doi/abs/10.1097/01.JU.0001191388.74345.c9.09 Preoperative Circulating Tumor DNA Predicts Upstaging and Recurrence in High-Risk Nonmuscle-Invasive Bladder Cancer Undergoing Radical Cystectomyhttps://pubmed.ncbi.nlm.nih.gov/41843048/ --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Fundraising is relationship building, but too many donor conversations feel disconnected, repetitive, and transactional. Enter the “Donor Waltz”. A three-step sequence of conversations designed to move donors from discovery to alignment, to meaningful commitment. Donors experience philanthropy emotionally, not operationally, and organizations that fail to find the emotional journey risk losing momentum, trust, and transformational opportunities. When fundraisers learn to sequence conversations, donor relationships begin to feel less like a checklist and more like a partnership.

Send us a message.We open with Daniel Arnold's new book You Are What You Do from Loose Joints — the sequencing, the blank pages, the editor's role — and end up on a harder question: what happens when you spend a decade on something and the first question someone asks is "what's next?" We talk through Josh Safdie's account of finishing Uncut Gems and why that question lands like an insult, and whether there's also something honest, even useful, about just moving on.That leads into the photo walk question: can you actually make work when you're with other people, or is this a medium that demands solitude? We use it as a way into what we think is genuinely missing from the Omaha creative scene — not talent, but the kind of competitive pressure that only comes from being around people operating at a high level and taking it seriously. We draw a line between community (people talking about ideas) and scene (people making work and raising the floor for each other).We also get into the difference between finding something valuable and making something from nothing, what it actually takes to own the label of photographer or writer without feeling like you're lying, and why "what's the point?" is the specific thought pattern that keeps you consuming instead of working. The answer, more or less: momentum is the point. -AiSupport the show If you enjoyed this episode, please consider giving us a rating and/or a review. We appreciate and try to read all of them. Thanks for listening, and we'll see you in the next episode. Links To Everything: Video Version of The Podcast: https://geni.us/StudioSessionsYT Matt's YouTube Channel: https://geni.us/MatthewOBrienYT Matt's 2nd Channel: https://geni.us/PhotoVideosYT Alex's YouTube Channel: https://geni.us/AlexCarterYT Matt's Instagram: https://geni.us/MatthewIG Alex's Instagram: https://geni.us/AlexIG 

There is a crucial difference between timelines and sequences, and if you want jurors to see your case as plainly as you see it, you need to pay close attention. Today we explore not just how timelines help jurors understand the case quickly, but why that is: the psychology and brain science behind retaining information. Timelines are a curated visual picture of the case, sequencing is about the order of presenting evidence. Similar, yet each with their own distinct psychologies. I know, not all lawyers use timelines, but they can be very effective, and focus groups help you recognize and fine tune what is most likely to register with juries. We want to make things as clear as possible for the jury, so don't lose your jury because you're jumping around the timeline. Logic, clarity and chronology that are structured and presented well can make all the difference. If you want to test your timeline and sequencing presentation on a focus group, book a free call with me and let's get set up:   https://www.calendly.com/elizabethlarrick   In this episode, we cover: How cognitive science shows that the first information is often assumed to be the first event. Why sequencing is essential for guiding jurors to a conclusion. How focus groups can help identify key events for timelines. Why overloading jurors with information can lead to confusion and undermine your case. Both timelines and sequencing are necessary for effective persuasion. Further links and references from this episode: Episode 158: Trial Strategy v. Trial Tactics New Blog post: Which Virtual Focus Group does Your Case Need? You can also watch today's episode on my YouTube Channel: Trial Strategy in Action: Timelines, Sequencing, and What Wins [Ep 167]   Follow and Review: We'd love for you to follow us if you haven't yet. Click that purple '+' in the top right corner of your Apple Podcasts app. We'd love it even more if you could drop a review or 5-star rating over on Apple Podcasts. Simply select "Ratings and Reviews" and "Write a Review" then a quick line with your favorite part of the episode. It only takes a second and it helps spread the word about the podcast. Don't miss out on the Trial Lawyer Prep Newsletter that is delivered right to your email with extra tips and 'how to' information. Join the newsletter here: www.larricklawfirm.com/connect

Trump's Raúl Castro move and what it signals for Cuba. Patrick Bet-David and the panel explain why the 1996 Brothers to the Rescue shootdown indictment matters now, call out Obama's friendly Cuba photo ops, and debate whether Trump is quietly setting up post-Castro regime change.

Sequences fail when every touch feels like a copy-paste template with no connecting thread.Buyers don't respond to volume, they respond to relevance and a message that feels like it was written for them.This session teaches a repeatable system for building cadences that match how buyers actually decide today. AI handles the research, variation, and follow-up drafts, you stay in control of the narrative.You'll walk through the cadence blueprint live, from touch count and channel roles to the frameworks that keep each step distinct. Every touch gets a job: add new value, new proof, or a new angle.You'll Learn:A cadence blueprint built for today's buyer, including touch count and channel role3 to 5 email frameworks you can plug into any sequence and use AI to generate variationsHow to keep follow-ups from sounding automated and what to do when prospects go quietThe Speakers:Jed Mahrle and Megan HustonIf you want to catch The Daily Sales Show live, join hereFollow Sell Better to get the latest actionable tactics from sales pros at the top of their gameExplore our YouTube ChannelThank you to our sponsors: ZoomInfo

Today, we are breaking down Auto1, and this is an interesting episode because we are tackling a business that most US listeners will not be familiar with, even though it resembles names they already know well. Our guest is Harrison Moot, co-founder and CIO of Sandstone, who walks us through Europe's largest vertically integrated online marketplace for used cars. Auto1 is often shorthanded as the Carvana of Europe, and the comparison directionally fits, but the differences are what make the company worth understanding on its own terms. The core of the conversation is how Harrison frames the company. He argues that Auto1 is best understood as a pan-European clearing house for used vehicles rather than a dealer with a website, and that the model only works because the company built its consumer sourcing engine and its wholesale dealer liquidity for nearly a decade before ever launching the consumer retail business. Owning the sourcing, logistics, refurbishment, and financing stack across thirty fragmented national markets gives Auto1 a pricing and routing advantage that local dealers and asset-light classifieds cannot replicate. Please enjoy this Breakdown of Auto1. For the full show notes, transcript, and links to the best content to learn more, check out the episode page⁠⁠⁠⁠⁠⁠⁠ here.⁠⁠⁠⁠⁠⁠⁠ ----- Become a Colossus member to get our quarterly print magazine and private audio experience, including exclusive profiles and early access to select episodes. Subscribe at ⁠colossus.com/subscribe⁠. ----- This episode is brought to you by⁠⁠⁠⁠ ⁠Portrait Analytics⁠⁠⁠⁠⁠ - your centralized resource for AI-powered idea generation, thesis monitoring, and personalized report building. Built by buy-side investors, for investment professionals. We work in the background, helping surface stock ideas and thesis signposts to help you monetize every insight. In short, we help you understand the story behind the stock chart, and get to "go, or no-go" 10x faster than before. Sign-up for a free trial today at ⁠⁠⁠⁠⁠portraitresearch.com⁠⁠⁠⁠⁠ ----- Stay up to date on all our podcasts by signing up to Colossus Weekly, our quick dive every Sunday highlighting the top business and investing concepts from our podcasts and the best of what we read that week. Sign up here. ----- Editing and post-production work for this episode was provided by The Podcast Consultant (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://thepodcastconsultant.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). Timestamps (00:00:00) Welcome to Business Breakdowns (00:03:35) Auto1 Business Overview  (00:07:06) European Market & C2B Model  (00:12:31) Founding Story & Sequencing  (00:16:39) Why Cazoo Failed  (00:16:42) Cazoo vs. Auto1 Approach  (00:18:29) How a Transaction Works  (00:22:11) Dealer Buying Patterns  (00:25:49) Retail vs. Wholesale  (00:26:18) Consumer Financing & ABS  (00:27:57) ABS Lowers Funding Costs  (00:28:16) Unit Economics by Segment  (00:32:37) Network Effects & Data Moat  (00:37:35) Path to Margin Expansion  (00:42:23) Balance Sheet & Working Capital  (00:44:40) Four Growth Levers  (00:48:27) Dealers: Customers Not Competitors  (00:53:17) Four Key Business Risks  (00:54:12) Inventory Risk & Mitigants  (00:58:32) Valuation Framework & Multiples  (01:03:14) Vertical Integration & Capital Cycles

With over 30 years in high performance sport, Ben Sporer has seen what it takes to be successful at the highest level of sport. From Canadian Olympic athletes to the Vancouver Whitecaps of the MLS, Ben has made a career on being clear and intentional about the goals of his program. So where do we […] The post Ben Sporer on Sequencing Training, Clear Objectives and Marginal Gains appeared first on Robertson Training Systems.

David Bell, co-founder of Idea Farm Ventures and early investor behind Warby Parker, Harry's, and Diapers.com, and CJ break down how consumer investing works. They cover why durable consumer companies require more than clean unit economics, how to apply SaaS-style thinking to businesses without contracts, and why the best opportunities often live in boring gray space.—SPONSORS:EY works with high-growth tech companies to navigate the messy realities of scaling—from regulatory requirements to IPO readiness. By helping teams get it right early and often, EY lets founders stay focused on building while reducing risk as they grow. Learn more at https://www.ey.com/techstartupsSpendHound is a SaaS spend management platform built for finance and procurement teams that want visibility and leverage in every deal. By tracking all your software, benchmarking pricing across thousands of vendors, and surfacing contracts and renewals, SpendHound helps you stop overpaying and negotiate with confidence. Trusted by teams at ZoomInfo and Hootsuite. Get started at https://www.spendhound.com/cjBrex is an intelligent finance platform that combines corporate cards, built-in expense management, and AI agents to eliminate manual finance work. By automating expense reviews and reconciliations, Brex gives CFOs more time for the high-impact work that drives growth. Join 35,000+ companies like Anthropic, Coinbase, and DoorDash at https://www.brex.com/metricsAleph is a modern FP&A platform built for teams that want more than another planning tool. By connecting your ERP, CRM, and other systems into one trusted data layer with AI workflows, Aleph helps you move faster with real-time insights. Get a personalized demo at https://www.getaleph.com/runRightRev is an automated revenue recognition platform built for teams that have outgrown spreadsheets and billing tool workarounds. It handles high-volume subscriptions, usage-based contracts, and mid-cycle upgrades, so you can scale without scrambling at month-end. For RevRec that keeps your books clean, visit https://www.rightrev.com/CJRillet is an AI-native ERP built for modern finance teams that want to replace NetSuite and close faster. With revenue recognition, close management, multi-entity support, and native Stripe and Salesforce integrations, Rillet helps scaling companies run their finance stack in one place. Hundreds of teams, including Windsurf and Mercor, use Rillet to make the zero-day close real. Book a demo at https://www.rillet.com/cj—Mostly Talent: https://mostlymetrics.typeform.com/to/cLTxtAsNGuest: https://www.linkedin.com/in/david-bell-086820/Company: https://www.ideafarmventures.com/CJ: https://www.linkedin.com/in/cj-gustafson-13140948/Mostly metrics: https://www.mostlymetrics.com—TIMESTAMPS:0:00 Preview and intro3:16 Edge: economics and psychology5:21 Best ideas in boring gray space5:41 Functional, emotional, and symbolic value7:08 Grüns gummies and divisibility9:02 Sponsors — EY | SpendHound | Brex12:31 Ideation: personal pain vs. market analysis13:17 Diapers.com and the Starbucks origin story16:00 Warby Parker: asking why16:33 LTV to CAC in D2C18:02 Retention math: 85 to 90% can double LTV19:00 Milkman and recurring vs. reoccurring20:42 Trust economics22:38 Warby stores boost online sales22:58 Sponsors — Aleph | RightRev | Rillet26:12 Away store as advertising27:46 Warby discovery: dots on a map30:10 Home try-on word of mouth value32:09 D2C unit economics mistakes34:55 Innovating on distribution35:50 Touchland in Sephora: right channel, right signal37:00 Capital allocation: margin and low CAC first39:18 Sequencing: people, brand, then inventory40:58 Product vs. brand: the 8x10 thought experiment42:23 Consumer monetization shifts45:45 The gravity framework50:32 Isolation principle: most underused lever52:36 Working backwards from exit at day zero57:23 What if your business isn't venture scale?59:32 Book plug: Founders Gold1:00:25 Credits

In this episode of Maximize Your Hunt, Jon Teater explores advanced hinge cutting techniques, timber management, and food plot strategies to enhance wildlife habitat and hunting success. Host shares expert insights on tree selection, structure creation, and balancing timber and habitat goals. Key topics include hinge cutting techniques and purpose, tree species selection and management, creating cover and structure for wildlife, balancing timber production with habitat needs   Takeaways Mastering Hinge Cutting for Better Wildlife Habitat 10 Expert Tips for Timber and Habitat Management   Social https://whitetaillandscapes.com/ https://www.facebook.com/whitetaillandscapes/ https://www.instagram.com/whitetail_landscapes/?hl=en Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The better you get at seeing opportunity, the worse you get at finishing anything. It turns out the same brain wiring that makes curious, growth-oriented people so interesting to talk to also makes them spectacularly bad at committing to one thing. In this episode, we explore the surprisingly rich psychology of focus — from what Taylor Swift's 16 dress changes per concert reveal about sequencing your ambitions, to a landmark study showing that how others perceive your potential literally changes what you become. It's equal parts neuroscience, life philosophy, and one man's genuine attempt to understand what wearing a dress taught him about staying focused. Why your potential is only as useful as your ability to narrow it The science behind why commitment feels like loss — and how to reframe it How to build a life with many chapters without living them all at once Funny, counterintuitive, and oddly practical — this episode might be the permission slip you didn't know you needed. SPONSORS

Send us Fan MailWhen Cash Feels Safer Than the Market: Funding Big Projects, Managing Risk, and Avoiding Tax TrapsHunter Kelly discusses a client case (names changed) involving Mark and Lauren, who earn just over $300,000, have nearly $1 million in retirement savings, and $100,000 cash while considering a $175,000–$180,000 pool project. They explored HELOC/pool loans but were uncomfortable with added debt, so they chose to delay until Mark's July bonus and retention payment arrive, including temporarily reducing his 403(b) contributions to increase short-term liquidity. The episode also covers Mark moving about $700,000 of his 403(b) into a money market due to market fears, the risks of staying in cash, and using a rules-based reentry plan and more fitting allocation. Kelly explains capital loss limits ($3,000 against ordinary income with carryforwards) and a backdoor Roth IRA reporting error on Form 8606 that, once corrected, saved about $1,000, emphasizing sequencing and broader advisor value beyond investments.00:00 Welcome and Setup00:46 Meet Mark and Lauren02:23 Pool Project Costs04:31 Debt vs Peace of Mind05:42 Waiting for Bonus Cash07:33 Pause 403b for Liquidity09:10 Moved Retirement to Cash11:56 Rules Based Reentry Plan14:08 Breakeven Bias and Purpose17:00 Capital Losses Explained19:54 Backdoor Roth Reporting23:03 Sequencing and Takeaways26:02 Wrap Up and DisclaimerCheck out the Palm Valley Wealth Management WebsitePalmValleywm.comCheck us out on InstagramLinkedIn FacebookListen to the Podcast Here! AppleSpotify

This week's show covers the sequencing of retirement withdrawals, municipal bonds, backdoor Roth contributions, gifting, and lots more!

In this episode, Hannah turns the mic on Celest to explore one of the most important shifts happening in modern yoga teaching: moving beyond muscles and into the nervous system.If you've ever felt stuck in your practice, confused by why something isn't improving, or unsure how to evolve your teaching, this conversation opens a completely new lens.Together, they unpack what sequencing really means from a neurological perspective, why traditional “build up to a pose” thinking can fall short, and how simple changes in input can completely transform how a body moves and feels.This is not about adding complexity. It's about understanding what's actually driving movement, safety and progress.In this episode, we explore:Why sequencing is more than arranging poses and what's actually happening in the brainThe role of sensory inputs, including vision, balance and internal awareness, in movement and performance Why strength and flexibility alone don't guarantee progress in poses like Pincha MayurasanaHow the nervous system determines whether a pose feels safe or threateningThe hidden reasons behind plateaus, asymmetries and “stuck” patternsHow past experiences, stress and injury history shape what happens on the matWhy repeating the same drills doesn't always lead to changeThe emotional and psychological layers that influence physical practiceCelest also shares her own journey from a purely biomechanical approach to integrating neuro-based work, including the challenges of learning and teaching this in real time.The conversation closes with a powerful reminder: your body is not failing you. It is responding to the information it receives.About Alba Yoga Academy⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Learn more with Alba Yoga Academy⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Learn more about our Yoga Teacher Training here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Watch our extensive library of YouTube videos.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow Hannah on Instagram.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow Celest on Instagram ⁠⁠⁠⁠

Today, host John Norlin shares a strategy called Grandma's Rule, a practical, research-backed approach to building predictability into the classroom through first-then scheduling and visual routines. John walks through why predictable environments lead to regulation, engagement, and ultimately learning, and how educators can set this up in a way that increases student motivation from the start. This episode is part of the CharacterStrong Weekly series — short, immediately applicable strategies educators can put to work the same day. In this episode, John offers important reminders for educators and leaders: Students crave predictability, when they can anticipate what is coming and why, they are better regulated and more ready to learn. First-then scheduling makes routines visible and explicit, giving students something to reference and helping educators get ahead of behavior proactively. Sequencing preferred and less preferred activities strategically increases student motivation without requiring more time or resources. Learn More About CharacterStrong:  Access FREE MTSS Curriculum Samples Request a Quote Today! Learn more about CharacterStrong Implementation Support Visit the CharacterStrong Website

Therapy, Maintenance, and Relapsed/Refractory SequencingThis week, we kick off the first of our myeloma capstone roundtable discussions with two experts who treat myeloma every single day. We welcome back Dr. Manni Mohyuddin from the Huntsman Cancer Institute at the University of Utah, and introduce a new friend of the show, Dr. Adeel Khan from UT Southwestern. In part two, we cover three practical and rapidly evolving topics: the role of MRD testing in guiding treatment decisions, how to individualize maintenance therapy in 2026, and how to approach sequencing of CAR-T and bispecific therapies in the relapsed/refractory setting.In this week's show notes, we summarize the key thoughts about how our experts think about approach to their patients.If you have not already done so, be sure to check out Part 1 of this discussion!Content:- What are the practical implications of MRD-testing in myeloma treatment?- How do we think about maintenance therapy in the present day? - What therapies are on the horizon? - How do we approach management of younger patients with relapsed/refractory disease?- How do we approach bridging therapy? ** This episode is sponsored by Primum! To learn more, sign up for your free account, and to ask questions to Primum experts, visit primum.co/fellows. As a special bonus, one of our guests, Dr. Mohyuddin, is an expert on Primum ready for your questions!** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube

Points of Interest 00:01 – 02:30 – The Cost of Poor Sequencing: Marcel and Kristen introduce the core issue—agencies often apply the right tactics in the wrong order, leading to wasted effort and stalled profitability. 02:30 – 05:00 – The Insight Formula: They explain that data alone is meaningless without context, introducing the key concept that insight comes from comparing expectations to reality. 05:00 – 06:30 – Start with a Business Model: Agencies should begin by building a model of their business to define what success should look like before measuring performance. 06:30 – 08:30 – The Danger of Starting with Data: Many firms overinvest in tracking actuals first, only to realize they lack the benchmarks needed to interpret the data effectively. 08:30 – 10:30 – Why Expectations Come First: Establishing expectations is faster, requires no new data, and is essential for designing meaningful feedback loops. 10:30 – 12:30 – Misguided Pricing and Benchmarking: Agencies often rely on market benchmarks instead of internal cost structures, leading to misaligned pricing and profitability issues. 12:30 – 14:30 – Framework vs. Frankenstein Metrics: Combining disconnected industry formulas creates inconsistent and unreliable financial insights, highlighting the need for a unified framework. 14:30 – 17:00 – Forecasting as the Next Step: Once a model is established, agencies must forecast workload and capacity, starting with clear scope and effort assumptions. 17:00 – 20:00 – The Precision Trap in Forecasting: Overly detailed planning creates friction and reduces adaptability; executive-level forecasting should prioritize accuracy over precision. 20:00 – 22:30 – The Power of Forecasting Without Time Tracking: A strong forecast can provide meaningful insight even without detailed time-tracking data. 22:30 – 25:30 – Installing Feedback Loops: Feedback loops help refine assumptions and uncover operational issues by comparing planned vs. actual performance. 25:30 – 30:00 – Prioritizing Profitability Levers: Marcel outlines the correct order for improving profitability—starting with overhead (if needed), then utilization, followed by pricing (effective rate), and finally cost structure. Show Notes Connect with Kristen via LinkedIn Free Agency Toolkit Parakeeto Foundations Course Free access to our Model Platform Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the Oncology Brothers podcast, we kicked off a three-part series on colorectal cancer, starting with the current treatment algorithm. They are joined by Dr. Smitha Krishnamurthi, a GI medical oncologist from the Cleveland Clinic, who walks through the evolving standard of care from early-stage disease all the way to refractory metastatic settings. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Key topics discussed included: • The evolving role of ctDNA as both a prognostic and predictive tool in stage two and three colon cancer, including its utility in oligometastatic disease surveillance. • Neoadjuvant versus adjuvant immunotherapy in MSI-high resectable colon cancer, comparing the NICHE-2 and ATOMIC trial approaches and when to use each. • Single-agent versus dual checkpoint inhibition with Nivo-Ipi for MSI-high metastatic disease, based on CHECKMATE-8HW data showing a PFS hazard ratio of 0.21. • Sequencing strategies in RAS-mutant and RAS wild-type metastatic colorectal cancer, including the role of sidedness, anti-EGFR therapy, and refractory options like fruquintinib, TAS-102, and regorafenib. Join us for this comprehensive discussion on colorectal cancer management in 2026. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology! #ColorectalCancer, #MSIHigh, #BRAFV600E, #ctDNA, #GIOncology, #OncologyBrothers

Most yoga teachers are taught that sequencing should be creative, complex, and always different. But these common beliefs often making teaching harder -- and keep both teachers and students stuck.Support this show http://supporter.acast.com/yogaland. Hosted on Acast. See acast.com/privacy for more information.